Goldman Sachs
RGNX icon

Goldman Sachs’s Regenxbio RGNX Stock Holding History

Goldman Sachs’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,000
Closed -$1.19M – 5955
2018
Q1 		$1.19M Buy
+40,000
New +$1.16M ﹤0.01% 3936

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs's RGNX Position: Q1 2026 in Review

Goldman Sachs increased its Regenxbio (RGNX) stake by 3% in Q1 2026, buying an estimated $568K and bringing the position to 1,839,463 shares worth $15.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

Goldman Sachs first reported a position in RGNX in Q2 2016 and has held it in 40 quarters since. The position peaked at $33.1M in Q4 2020. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Goldman Sachs held 1,839,463 shares of Regenxbio worth $15.4M as of Q1 2026.
  • Goldman Sachs bought 54,026 Regenxbio shares in Q1 2026, an estimated $568K.
  • Regenxbio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2699 holding.
  • Goldman Sachs first reported a position in Regenxbio in Q2 2016 and has held it in 40 quarters since.
  • Goldman Sachs's Regenxbio position peaked at $33.1M in Q4 2020.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.